Michael P. Rettig

Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100

Bruno Nervi, Pablo Ramírez, Michael P. Rettig et al. · Blood · 2008 · 481 citations · Full text

Medicine, Oncology, Pharmacology +13

Immune Escape of Relapsed AML Cells after Allogeneic Transplantation

Matthew Christopher, Allegra A. Petti, Michael P. Rettig et al. · New England Journal of Medicine · 2018 · 471 citations · Full text

Medicine, Hematology, Immunology +14

An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies

Matthew Cooper, Jaebok Choi, Karl Staser et al. · Leukemia · 2018 · 394 citations · Full text

Medicine, Hematology, Oncology +14

A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia

Geoffrey L. Uy, Michael P. Rettig, Ibraheem Motabi et al. · Blood · 2012 · 388 citations · Full text

Medicine, Oncology, Pharmacology +15

Impact of Mobilization and Remobilization Strategies on Achieving Sufficient Stem Cell Yields for Autologous Transplantation

Iskra Pusic, Shi Yuan Jiang, Scott Landua et al. · Biology of Blood and Marrow Transplantation · 2008 · 349 citations · Full text

Medicine, Hematology, Oncology +17